Compare PRAA & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAA | TLRY |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | 170 | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.1M | 570.4M |
| IPO Year | 2002 | 2018 |
| Metric | PRAA | TLRY |
|---|---|---|
| Price | $18.49 | $4.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $24.50 | ★ $72.33 |
| AVG Volume (30 Days) | 897.1K | ★ 3.4M |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $1,201,837,000.00 | N/A |
| Revenue This Year | $2.01 | $8.79 |
| Revenue Next Year | $2.53 | $19.98 |
| P/E Ratio | $25.03 | ★ N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $10.25 | $0.55 |
| 52 Week High | $22.55 | $15.70 |
| Indicator | PRAA | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 36.85 |
| Support Level | $16.60 | $0.77 |
| Resistance Level | $19.29 | $4.85 |
| Average True Range (ATR) | 0.89 | 0.23 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 79.59 | 32.31 |
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.